Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

Pfizer 's (PFE -0.28%) management team is confident in its 2025 opportunities. *Stock prices used were the afternoon prices of May 20, 2025. The video was published on May 22, 2025.

Pfizer's built from many pieces that are moving in opposite directions. To make sure this stock isn't a yield trap destined to slash its dividend payout in the near term, let's weigh the good news ...

So far this year, Pfizer’s stock has declined 13.7% compared with a decrease of 3.6% for the industry. Pfizer Stock Performance Image Source: Zacks Investment Research ...

These might not immediately impact its stock performance, but together with its pipeline goals, they could eventually lead to much stronger returns. Pfizer's decision to license SSGJ-707 doesn't ...

Pfizer's decision to license SSGJ-707 doesn't make its stock a buy in and of itself. However, the drug candidate is another valuable asset that will be part of the company's plan to improve its ...